{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T00:33:19Z","timestamp":1773189199293,"version":"3.50.1"},"reference-count":31,"publisher":"Oxford University Press (OUP)","issue":"11","license":[{"start":{"date-parts":[[2021,5,31]],"date-time":"2021-05-31T00:00:00Z","timestamp":1622419200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"DOI":"10.13039\/100007313","name":"University of Texas MD Anderson Cancer Center","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007313","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100016373","name":"Broach Foundation for Brain Cancer Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016373","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["CA247970"],"award-info":[{"award-number":["CA247970"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["P30CA16672"],"award-info":[{"award-number":["P30CA16672"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["NCI# CA0166772"],"award-info":[{"award-number":["NCI# CA0166772"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,11,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Oncolytic adenoviruses are promising new treatments against solid tumors, particularly for glioblastoma (GBM), and preclinical models are required to evaluate the mechanisms of efficacy. However, due to the species selectivity of adenovirus, there is currently no single animal model that supports viral replication, tumor oncolysis, and a virus-mediated immune response. To address this gap, we took advantage of the Syrian hamster to develop the first intracranial glioma model that is both adenovirus replication-permissive and immunocompetent.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We generated hamster glioma stem-like cells (hamGSCs) by transforming hamster neural stem cells with hTERT, simian virus 40 large T antigen, and h-RasV12. Using a guide-screw system, we generated an intracranial tumor model in the hamster. The efficacy of the oncolytic adenovirus Delta-24-RGD was assessed by survival studies, and tumor-infiltrating lymphocytes (TILs) were evaluated by flow cytometry.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>In vitro, hamGSCs supported viral replication and were susceptible to Delta-24-RGD mediated cell death. In vivo, hamGSCs consistently developed into highly proliferative tumors resembling high-grade glioma. Flow cytometric analysis of hamster gliomas revealed significantly increased T-cell infiltration in Delta-24-RGD infected tumors, indicative of immune activation. Treating tumor-bearing hamsters with Delta-24-RGD led to significantly increased survival compared to hamsters treated with phosphate buffered saline (PBS).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This adenovirus-permissive, immunocompetent hamster glioma model overcomes the limitations of previous model systems and provides a novel platform to study the interactions between tumor cells, the host immune system, and oncolytic adenoviral therapy; understanding of which will be critical to implementing oncolytic adenovirus in the clinic.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/neuonc\/noab128","type":"journal-article","created":{"date-parts":[[2021,5,29]],"date-time":"2021-05-29T10:57:42Z","timestamp":1622285862000},"page":"1911-1921","source":"Crossref","is-referenced-by-count":15,"title":["An immune-competent, replication-permissive Syrian Hamster glioma model for evaluating Delta-24-RGD oncolytic adenovirus"],"prefix":"10.1093","volume":"23","author":[{"given":"Lynette M","family":"Phillips","sequence":"first","affiliation":[{"name":"Department of Neurosurgery, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA"},{"name":"The Brain Tumor Center, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shoudong","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA"},{"name":"The Brain Tumor Center, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joy","family":"Gumin","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA"},{"name":"The Brain Tumor Center, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marc","family":"Daou","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA"},{"name":"The Brain Tumor Center, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"Ledbetter","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA"},{"name":"The Brain Tumor Center, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA"},{"name":"The Brain Tumor Center, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sanjay","family":"Singh","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA"},{"name":"The Brain Tumor Center, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brittany C","family":"Parker Kerrigan","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA"},{"name":"The Brain Tumor Center, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anwar","family":"Hossain","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA"},{"name":"The Brain Tumor Center, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3163-480X","authenticated-orcid":false,"given":"Ying","family":"Yuan","sequence":"additional","affiliation":[{"name":"Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Candelaria","family":"Gomez-Manzano","sequence":"additional","affiliation":[{"name":"The Brain Tumor Center, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA"},{"name":"Department of Neuro-Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan","family":"Fueyo","sequence":"additional","affiliation":[{"name":"The Brain Tumor Center, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA"},{"name":"Department of Neuro-Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Frederick F","family":"Lang","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA"},{"name":"The Brain Tumor Center, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2021,5,31]]},"reference":[{"issue":"2","key":"2021110300462725700_CIT0001","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1056\/NEJMoa1716435","article-title":"Recurrent glioblastoma treated with recombinant poliovirus","volume":"379","author":"Desjardins","year":"2018","journal-title":"N Engl J Med."},{"issue":"10","key":"2021110300462725700_CIT0002","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1093\/neuonc\/noy075","article-title":"Durable complete responses in some recurrent high-grade glioma patients treated with Toca 511 + Toca FC","volume":"20","author":"Cloughesy","year":"2018","journal-title":"Neuro Oncol."},{"issue":"8","key":"2021110300462725700_CIT0003","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1093\/neuonc\/now002","article-title":"Phase II multicenter study of gene-mediated cytotoxic immunotherapy as adjuvant to surgical resection for newly diagnosed malignant glioma","volume":"18","author":"Wheeler","year":"2016","journal-title":"Neuro Oncol."},{"issue":"9","key":"2021110300462725700_CIT0004","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1093\/jnci\/95.9.652","article-title":"Preclinical characterization of the antiglioma activity of a tropism-enhanced adenovirus targeted to the retinoblastoma pathway","volume":"95","author":"Fueyo","year":"2003","journal-title":"J Natl Cancer Inst."},{"issue":"14","key":"2021110300462725700_CIT0005","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2017.75.8219","article-title":"Phase I study of DNX-2401 (Delta-24-RGD) oncolytic adenovirus: replication and immunotherapeutic effects in recurrent malignant glioma","volume":"36","author":"Lang","year":"2018","journal-title":"J Clin Oncol"},{"issue":"14","key":"2021110300462725700_CIT0006","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1200\/JCO.2017.77.3192","article-title":"Oncolytic Virotherapy for Malignant Gliomas","volume":"36","author":"Forsyth","year":"2018","journal-title":"J Clin Oncol."},{"issue":"18","key":"2021110300462725700_CIT0007","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1093\/jnci\/djm102","article-title":"Examination of the therapeutic potential of Delta-24-RGD in brain tumor stem cells: role of autophagic cell death","volume":"99","author":"Jiang","year":"2007","journal-title":"J Natl Cancer Inst."},{"issue":"5","key":"2021110300462725700_CIT0008","doi-asserted-by":"crossref","first-page":"e97407","DOI":"10.1371\/journal.pone.0097407","article-title":"Delta-24-RGD oncolytic adenovirus elicits anti-glioma immunity in an immunocompetent mouse model","volume":"9","author":"Jiang","year":"2014","journal-title":"PLoS One."},{"issue":"4","key":"2021110300462725700_CIT0009","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/0168-1702(89)90026-9","article-title":"Restricted replication of human adenovirus type 5 in mouse cell lines","volume":"14","author":"Blair","year":"1989","journal-title":"Virus Res."},{"issue":"8","key":"2021110300462725700_CIT0010","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1038\/cgt.2009.6","article-title":"INGN 007, an oncolytic adenovirus vector, replicates in Syrian hamsters but not mice: comparison of biodistribution studies","volume":"16","author":"Ying","year":"2009","journal-title":"Cancer Gene Ther."},{"key":"2021110300462725700_CIT0011","doi-asserted-by":"crossref","first-page":"S271","DOI":"10.1093\/infdis\/jiv203","article-title":"Natural Immunity to Ebola Virus in the Syrian Hamster Requires Antibody Responses","volume":"212","author":"Prescott","year":"2015","journal-title":"J Infect Dis."},{"issue":"2","key":"2021110300462725700_CIT0012","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1111\/imm.12116","article-title":"The adaptive immune response does not influence hantavirus disease or persistence in the Syrian hamster","volume":"140","author":"Prescott","year":"2013","journal-title":"Immunology."},{"issue":"3","key":"2021110300462725700_CIT0013","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1158\/0008-5472.CAN-05-3497","article-title":"Syrian hamster as a permissive immunocompetent animal model for the study of oncolytic adenovirus vectors","volume":"66","author":"Thomas","year":"2006","journal-title":"Cancer Res."},{"issue":"2","key":"2021110300462725700_CIT0014","doi-asserted-by":"crossref","first-page":"326","DOI":"10.3171\/jns.2000.92.2.0326","article-title":"An implantable guide-screw system for brain tumor studies in small animals","volume":"92","author":"Lal","year":"2000","journal-title":"J Neurosurg."},{"issue":"1","key":"2021110300462725700_CIT0015","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1128\/JVI.02184-14","article-title":"Amplified and persistent immune responses generated by single-cycle replicating adenovirus vaccines","volume":"89","author":"Crosby","year":"2015","journal-title":"J Virol."},{"issue":"10","key":"2021110300462725700_CIT0016","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.1038\/mt.2009.156","article-title":"Pre-existing immunity and passive immunity to adenovirus 5 prevents toxicity caused by an oncolytic adenovirus vector in the Syrian hamster model","volume":"17","author":"Dhar","year":"2009","journal-title":"Mol Ther."},{"issue":"48","key":"2021110300462725700_CIT0017","first-page":"2348","article-title":"Isolation of brain and spinal cord mononuclear cells using percoll gradients","author":"Pino","year":"2011","journal-title":"J Vis Exp"},{"issue":"15","key":"2021110300462725700_CIT0018","doi-asserted-by":"crossref","first-page":"6464","DOI":"10.1128\/MCB.25.15.6464-6474.2005","article-title":"Transformation of human and murine fibroblasts without viral oncoproteins","volume":"25","author":"Boehm","year":"2005","journal-title":"Mol Cell Biol."},{"issue":"2","key":"2021110300462725700_CIT0019","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1016\/j.cell.2013.09.034","article-title":"The somatic genomic landscape of glioblastoma","volume":"155","author":"Brennan","year":"2013","journal-title":"Cell."},{"issue":"15","key":"2021110300462725700_CIT0020","doi-asserted-by":"crossref","first-page":"6021","DOI":"10.1073\/pnas.1303607110","article-title":"TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal","volume":"110","author":"Killela","year":"2013","journal-title":"Proc Natl Acad Sci U S A."},{"issue":"7015","key":"2021110300462725700_CIT0021","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1038\/nature03128","article-title":"Identification of human brain tumour initiating cells","volume":"432","author":"Singh","year":"2004","journal-title":"Nature."},{"issue":"14","key":"2021110300462725700_CIT0022","doi-asserted-by":"crossref","first-page":"3894","DOI":"10.1158\/0008-5472.CAN-17-0468","article-title":"Oncolytic Adenovirus and Tumor-Targeting Immune Modulatory Therapy Improve Autologous Cancer Vaccination","volume":"77","author":"Jiang","year":"2017","journal-title":"Cancer Res."},{"key":"2021110300462725700_CIT0023","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/B978-0-12-398342-8.00003-3","article-title":"Chapter three\u2013Syrian hamster as an animal model to study oncolytic adenoviruses and to evaluate the efficacy of antiviral compounds","volume":"115","author":"Wold","year":"2012","journal-title":"Adv Cancer Res."},{"key":"2021110300462725700_CIT0024","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.vetimm.2016.12.003","article-title":"Characterisation of monoclonal antibodies specific for hamster leukocyte differentiation molecules","volume":"183","author":"Rees","year":"2017","journal-title":"Vet Immunol Immunopathol."},{"issue":"11","key":"2021110300462725700_CIT0025","doi-asserted-by":"crossref","first-page":"e1358839","DOI":"10.1080\/2162402X.2017.1358839","article-title":"In-depth immunophenotyping of patients with glioblastoma multiforme: Impact of steroid treatment","volume":"6","author":"Chitadze","year":"2017","journal-title":"Oncoimmunology."},{"issue":"3","key":"2021110300462725700_CIT0026","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1007\/s11060-017-2395-y","article-title":"Neutrophil-lymphocyte ratio dynamics during concurrent chemo-radiotherapy for glioblastoma is an independent predictor for overall survival","volume":"132","author":"Mason","year":"2017","journal-title":"J Neurooncol."},{"issue":"4","key":"2021110300462725700_CIT0027","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1038\/cgt.2014.13","article-title":"Cycles of transient high-dose cyclophosphamide administration and intratumoral oncolytic adenovirus vector injection for long-term tumor suppression in Syrian hamsters","volume":"21","author":"Dhar","year":"2014","journal-title":"Cancer Gene Ther."},{"issue":"10","key":"2021110300462725700_CIT0028","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1038\/mt.2008.162","article-title":"Immunosuppression enhances oncolytic adenovirus replication and antitumor efficacy in the Syrian hamster model","volume":"16","author":"Thomas","year":"2008","journal-title":"Mol Ther."},{"issue":"1","key":"2021110300462725700_CIT0029","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1158\/1078-0432.CCR-16-0477","article-title":"The Efficacy of Oncolytic Adenovirus Is Mediated by T-cell Responses against Virus and Tumor in Syrian Hamster Model","volume":"23","author":"Li","year":"2017","journal-title":"Clin Cancer Res."},{"issue":"5","key":"2021110300462725700_CIT0030","doi-asserted-by":"crossref","first-page":"e97495","DOI":"10.1371\/journal.pone.0097495","article-title":"The in vivo therapeutic efficacy of the oncolytic adenovirus Delta24-RGD is mediated by tumor-specific immunity","volume":"9","author":"Kleijn","year":"2014","journal-title":"PLoS One."},{"issue":"Pt 5","key":"2021110300462725700_CIT0031","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1093\/brain\/aww046","article-title":"Corticosteroids compromise survival in glioblastoma","volume":"139","author":"Pitter","year":"2016","journal-title":"Brain."}],"container-title":["Neuro-Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/neuro-oncology\/advance-article-pdf\/doi\/10.1093\/neuonc\/noab128\/38981581\/noab128.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/neuro-oncology\/article-pdf\/23\/11\/1911\/41064117\/noab128.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/neuro-oncology\/article-pdf\/23\/11\/1911\/41064117\/noab128.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,2]],"date-time":"2021-11-02T20:47:28Z","timestamp":1635886048000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/neuro-oncology\/article\/23\/11\/1911\/6290257"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,31]]},"references-count":31,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2021,5,31]]},"published-print":{"date-parts":[[2021,11,2]]}},"URL":"https:\/\/doi.org\/10.1093\/neuonc\/noab128","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.740216651.793587453","asserted-by":"object"}]},"ISSN":["1522-8517","1523-5866"],"issn-type":[{"value":"1522-8517","type":"print"},{"value":"1523-5866","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,11,1]]},"published":{"date-parts":[[2021,5,31]]}}}